Human Trials to Begin on Hepatitis C Drug TMC649128

[Guest guest]

Human Trials to Begin on Hepatitis C Drug TMC649128

After encouraging pre-clinical studies, Medivir and Tibotec are beginning a Phase 1a trial of their Hepatitis C nucleoside inhibitor.

Medivir Kicks Off Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128

Feb 16, 2011 (Close-Up Media via COMTEX) --

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, announced the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection.

The Company said TMC649128 is a nucleoside NS5B polymerase inhibitor that has already demonstrated an attractive pre-clinical profile. It is anticipated that this profile would see TMC649128 be used in combination with HCV directly acting antiviral agents, given their high genetic barrier to resistance and antiviral activity across multiple HCV genotypes.

Continue reading this entire article:http://www.tradingmarkets.com/news/stock-alert/mvrbf_medivir-kicks-off-phase-1a-trial-of-the-hepatitis-c-polymerase-inhibitor-tmc649128-1494826.html

http://www.hepatitis-central.com/mt/archives/2011/02/human_trials_to.html